Abstract
The purpose of the study was to determine the activity of natural killer (NK) cells in children with malignant tumors and the effect of interleukin-2 (IL-2) in enhancing NK-cell activity of these patients in vitro. The NK-cell activity in mononuclear cells of peripheral blood was measured by the 125 IUdR release assay. The mean level of NK-cell activity in children with cancer (16.52%) was significantly lower than that for normal controls (29.75%) and no significant difference of NK-cell activity was found between children with different cancers. After mononuclear cells were incubated with recombinant IL-2 (rIL-2), NK cells from 96% (22/23) of the samples showed augmented cytotoxicity. The levels of NK-cell activity of patients, either prior to therapy or with treatment (operation or chemotherapy), were very low (1.36%–30.69%; 6.17%–33.64%, respectively) before rIL-2 stimulation and significantly increased (15.41%–65.80%; 23.85%–49.36%, respectively) after stimulation, suggesting a potential therapeutic role for rIL-2 in the treatment of malignant solid tumors of childhood and providing a rationale for the clinical use of rIL-2.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ades-EW, Hinson-A (1986) Protective effect(s) of rIL-2 modulation. I. The effects of chemotherapeutic/cytotoxic agents on human natural killer cells and lymphokine-activated killer cells. J Immunopharmacol 8: 481–497
Alvarado CS, Findley HW, Chan WC, Hnath RS, Abdel Mageed A, Pais RC, Kutner MH, Ragab AH (1989) Natural killer cells in children with malignant solid tumors. Effect of recombinant alpha-interferon and interleukin-2 on natural killer cell function against tumor cell lines. Cancer 63: 83–89
Anderson TM, Ibayashi Y, Tokuda Y, Colquhoun SD, Holmes EC, Golub SH (1988) Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes. Cancer Res 48: 1180–1183
Bhagyam RC, Jarrett Zaczek D, Ferguson FG (1988) Activation of swine peripheral blood lymphocytes with human recombinant interleukin-2. Immunology 64: 607–613
Bleackley RC, Havele C, Paetkau V (1982) Cellular and molecular properties of an antigen-specific cytotoxic T-lymphocyte line. J Immunol 128: 758–767
Creekmore SP, Harris JE, Ellis TM, Braun DP, Cohen II, Bhoopalam N, Jassak PF, Cahill MA, Canzoneri CL, Fisher RI (1989) A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions. J Clin Oncol 7: 276–284
Domzig W, Stadler BM, Herberman RB (1983) Interleukin-2 dependence of human natural killer (NK) cell activity. J Immunol 130: 1970–1973
Gerson JM, Herberman RB (1980) Systemic and in situ natural killer activity in patients with NB. In: Evans AE(ed) Advances in neuroblastoma research. Raven Press, New York, pp 251–259
Goto T, Herberman RB, Maluish A, Strong DM (1983) Cyclic AMP as a mediator of prostaglandin E-induced suppression of human natural killer cell activity. J Immunol 130: 1350–1355
Hellstrom I, Hellström KE, Bill AH, Pierce GE, Yang JPS (1970) Studies on cellular immunity to human neuroblastoma cells. Int J Cancer 6: 172–188
Hofer KG, Hughes WL (1971) Radiotoxicity of intranuclear tritium, 125Iodine and 131Iodine. Radiation Research 47: 94–109
Kedar E, Ikdjiri BL, Timonen T, Bonnand GD, Reid J, Navarro NJ, Sredni B, Herberman RB (1983) Antitumor reactivity in vitro and in vivo of lymphocytes from normal donors and cancer patients propagated in culture with T-cell growth factor. Eur J Cancer Clin Oncol 19: 757–773
Masucci G, Masucci MG, Bejarano MT, Klein E (1983) Comparison of highly NK active human lymphocyte subsets separated by various procedures involving E. EA rosetting density gradients and adherence to immune complexes. J Immunol Methods 63: 57–67
Oldhan RK, Herberman RB (1973) Evaluation of cell-mediated cytotoxic reactivity against tumor associated antigens with 125I-iododeoxyuridine labelled target cells. J Immunol 111: 1862–1871
Ortaldo JR, Mason AT, Genard JP, Henderson LE, Farrar W, Hopkins III RF, Herberman RB, Rabin H (1984) Effects of natural and recombinant IL-2 on regulation of IFN production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects. J Immunol 133: 779–783
Phillips JH, Gemlo BT, Myers WW, Rayner AA, Lanier LL (1987) In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy. J Clin Oncol 5: 1933–1941
Schantz SP, Shillitoe EJ, Brown B (1986) Natural killer cell activity and head and neck cancer: a clinical assessment. J Natl Cancer Inst 77: 869–875
Shaw ARE, Bleackley RC, Merryweather JP, Barr PJ (1985) Modulation of human natural killer cell activity by recombinant human interleukin-2. Cell Immunol 91: 193–200
Steinhauer EH, Doyle AT, Reed J (1982) Defective natural cytotoxicity in patients with cancer: normal number of effector cells but decreased recycling capacity in patients with advanced disease. J Immunol 129: 2255–2259
Suzuki R, Handa K, Itoh K, Kumagai K (1983) Natural killer (NK) cells as a responder to interleukin-2 (IL-2). I. Proliferative response and establishment of cloned cells. J Immunol 130: 981–987
Trinchieri G, Matsumoto-Kobayashi M, Clark SC, Seehra J, London L, Perussia B (1984) Response of resting human periphral blood natural killer cells to interleukin-2. J Exp Med 160: 1147–1169
Author information
Authors and Affiliations
Additional information
Offprint requests to: She Yaxiong
Rights and permissions
About this article
Cite this article
Lu, X., She, Y., Yin, D. et al. Effect of interleukin-2 on natural killer-cell activity in children with malignant solid tumors. Pediatr Surg Int 6, 341–344 (1991). https://doi.org/10.1007/BF00178651
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00178651